| 生物活性 |
Cajanol is an isoflavanone isolated from the roots of Cajanus cajan (L.) Millsp. that inhibits cancer cell proliferation and induces apoptosis by promoting Bax expression, suppressing Bcl-2 expression, activating caspase-9 and caspase-3, inducing PARP cleavage, arresting the cell cycle at G2/M phase, generating ROS, disrupting mitochondrial membrane potential, and triggering cytochrome c release, while also inducing bacterial DNA damage, disrupting bacterial cell membranes, and exerting antibacterial activity in vitro, and it reduces PI3K expression, inhibits Akt and NF-κB phosphorylation, downregulates P-gp expression and transport function, restores the sensitivity of drug-resistant cancer cells to Paclitaxel, and suppresses the growth of Paclitaxel-resistant metastatic ovarian tumors, making it useful for research on breast cancer, ovarian cancer, and bacterial infections. |
体外研究 (In Vitro) |
Cajanol (0-316 μM; 24-72 h) 可呈时间和剂量依赖性强效抑制人乳腺癌 MCF-7 细胞的生长,72 h 后的 IC50 为 54.05 μM,48 h 后的 IC50 为 58.32 μM,24 h 后的 IC50 为 83.42 μM。 Cajanol (16-64 μM; 48 h) 可在人乳腺癌 MCF-7 细胞中诱导浓度依赖性的 G2/M 期细胞周期阻滞,诱导浓度依赖性凋亡,诱导细胞发生 DNA 片段化,诱导典型的凋亡核形态学改变,包括染色质固缩和碎裂,诱导 ROS 生成、线粒体膜电位破坏。 Cajanol (16-64 μM; 48 h) 可在人乳腺癌 MCF-7 细胞中诱导 caspase-3 和 caspase-9 激活,下调细胞中 Bcl-2 的表达并上调 Bax 的表达,诱导细胞中细胞色素 c 从线粒体向胞浆呈浓度依赖性释放,诱导 PARP 呈浓度依赖性剪切。 Cajanol (24 h) 可在体外抑制革兰氏阳性菌 (Staphylococcus epidermidis、Staphylococcus aureus、Bacillus subtilis) 和革兰氏阴性菌 (Escherichia coli、Proteus vulgaris、Pseudomonas aeruginosa) 菌株的生长,其中最敏感菌株 (Staphylococcus epidermidis、Staphylococcus aureus、Escherichia coli) 的 MIC 值为 98.90 μM,敏感性较低的菌株 (Bacillus subtilis、Proteus vulgaris、Pseudomonas aeruginosa) 的 MIC 值为 197.8 μM。 Cajanol (4-10 小时) 可在体外诱导大肠杆菌和金黄色葡萄球菌发生时间依赖性细胞死亡和膜损伤,诱导发生 DNA 切割。 Cajanol (2-16 μM; 72 h) 可浓度依赖性逆转 A2780/Taxol 和 A549/Taxol 细胞的 Paclitaxel (HY-B0015) 耐药性。 Cajanol (2-8 μM; 48 h) 可浓度依赖性地抑制 A2780/Taxol 细胞中 ABCB1 的 mRNA 表达、P-gp 蛋白。 Cajanol (2-8 μM; 48 h) 可通过降低 PI3K 表达、抑制 Akt 磷酸化及阻断 NF-κB/p65 磷酸化与核转位,以浓度依赖的方式抑制 A2780/Taxol 细胞中的 PI3K/Akt/NF-κB 信号通路。 Cajanol (2-8 μM; 2 h pre-incubation, 1 h co-incubation with rhodamine-123) 可浓度依赖性地抑制 A2780/Taxol 细胞中 P-gp 介导的外排活性,增加细胞内 rhodamine-123 的累积。
Cell Cytotoxicity Assay
| Cell Line: |
MCF-7 human breast cancer cells |
| Concentration: |
0, 9.88, 19.75, 39.5, 79, 158 and 316 μM |
| Incubation Time: |
24 h; 48 h; 72 h |
| Result: |
Inhibited MCF-7 cell growth in a time- and dose-dependent manner. Reached an IC50 value of 83.42 μM after 24 h treatment, 58.32 μM after 48 h treatment, and 54.05 μM after 72 h treatment. |
Cell Cycle Analysis
| Cell Line: |
MCF-7 human breast cancer cells |
| Concentration: |
0, 16, 32 and 64 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the G2/M phase cell population from 19.24% (16 μM) to 47.87% (64 μM), compared to 7.55% in untreated controls. |
Apoptosis Analysis
| Cell Line: |
MCF-7 human breast cancer cells |
| Concentration: |
0, 16, 32 and 64 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the percentage of annexinV-FITC binding MCF-7 cells in a concentration-dependent manner, reaching 12.84% (16 μM), 47.94% (32 μM), and 78.03% (64 μM). |
Western Blot Analysis
| Cell Line: |
MCF-7 human breast cancer cells |
| Concentration: |
16-64 μM |
| Incubation Time: |
48 h |
| Result: |
Decreased relative Bcl-2 expression from 66.89% (16 μM) to 47.20% (64 μM) in a concentration-dependent manner. Increased relative Bax expression from 186.36% (16 μM) to 341.36% (64 μM) in a concentration-dependent manner.\nDecreased relative mitochondrial cytochrome c expression from 87.93% (16 μM) to 19.40% (64 μM) in a concentration-dependent manner. Increased relative cytosolic cytochrome c expression from 190.04% (16 μM) to 503.91 % (64 μM) in a concentration-dependent manner.\nDecreased relative full-length PARP expression from 95.64% (16 μM) to 38.89% (64 μM) in a concentration-dependent manner. Increased cleaved PARP expression in a concentration-dependent manner, visible as an 85 kDa protein band with disappearance of the 116 kDa band. |
Cell Proliferation Assay
| Cell Line: |
A2780/Taxol paclitaxel-resistant ovarian cancer cells, A549/Taxol paclitaxel-resistant non-small cell lung cancer cells |
| Concentration: |
2, 4, 8, 16 μM |
| Incubation Time: |
72 h (co-incubated with paclitaxel) |
| Result: |
Reduced the Paclitaxel IC50 in A2780/Taxol cells from 35.85 μM to 25.67 μM (2 μM), 16.25 μM (4 μM), 6.54 μM (8 μM), and 6.05 μM (16 μM), with corresponding fold resistance values of 22.52, 14.51, 5.64, and 5.50, respectively. Reduced the paclitaxel IC50 in A549/Taxol cells from 289.34 μM to 189.43 μM (2 μM), 68.95 μM (4 μM), 27.9 μM (8 μM), and 23.76 μM (16 μM), with corresponding fold resistance values of 24.35, 9.01, 3.74, and 3.15, respectively. Exhibited an IC50 of 28.34 μM in A2780/Taxol cells and 87.78 μM in A549/Taxol cells when used alone. |
Real Time qPCR
| Cell Line: |
A2780/Taxol paclitaxel-resistant ovarian cancer cells |
| Concentration: |
2, 4, 8 μM |
| Incubation Time: |
48 h |
| Result: |
Concentration-dependently downregulated ABCB1 mRNA expression, with 8 μM reducing expression to ~10% of the control level. Did not significantly change expression of VEGF, MMP-9, Tubα1a, and Tubβ3 mRNA. |
Western Blot Analysis
| Cell Line: |
A2780/Taxol paclitaxel-resistant ovarian cancer cells |
| Concentration: |
2, 4, 8 μM |
| Incubation Time: |
48 h |
| Result: |
Concentration-dependently downregulated P-gp protein expression. Did not significantly change expression of VEGF, MMP-9, α-tubulin, βIII-tubulin, MRP1, MRP2, and LRP protein.\nConcentration-dependently reduced PI3K protein expression, inhibited Akt phosphorylation, and reduced NF-κB/p65 phosphorylation and nuclear translocation. Did not significantly change total Akt and total NF-κB/p65 protein expression. |
|